Alps Group Expands Exosome Pipeline Beyond CELESOME(+) Following Asthma and COPD Study Publication.
ByAinvest
Friday, Jan 30, 2026 8:03 am ET1min read
ALPS--
Alps Group Inc has announced a potential expansion of its exosome-related pipeline beyond the CELESOME(+) program. The announcement follows the publication of a preliminary retrospective clinical case series describing nebulized human umbilical cord mesenchymal stem cell-derived exosome therapy in patients with asthma and/or COPD. The study reports promising improvements in pulmonary function and stability in inflammatory markers with no significant adverse effects.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet